<!DOCTYPE html>
<html lang="zh">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2atrial of QBS72S in breast cancer brain metastases - PMC</title>
  <style>
    body {
      font-family: "Helvetica Neue", "Noto Sans TC", sans-serif;
      max-width: 720px;
      margin: 2em auto;
      padding: 0 1em;
      color: #333;
      line-height: 1.8;
      background: #fff;
    }
    h1, h2, h3 {
      text-align: center;
      color: #222;
    }
    .lang-switcher {
      text-align: center;
      margin-bottom: 2em;
    }
    .lang-btn {
      margin: 0 0.5em;
      padding: 0.4em 1em;
      border: none;
      background-color: #eee;
      border-radius: 4px;
      cursor: pointer;
      font-weight: bold;
    }
    .lang-btn.active {
      background-color: #007acc;
      color: white;
    }
    ul {
      padding-left: 1.2em;
    }
    a {
      color: #007acc;
      text-decoration: none;
    }
    a:hover {
      text-decoration: underline;
    }
    img {
      max-width: 100%;
      height: auto;
    }
    .share-block {
      text-align: center;
      margin: 1em 0 2em;
      font-size: 0.95em;
    }
    .share-block a svg {
      width: 24px;
      height: 24px;
      display: inline-block;
      vertical-align: middle;
      margin: 0 0.4em;
      transition: transform 0.2s ease;
      cursor: pointer;
    }
    .share-block a svg:hover {
      transform: scale(1.2);
    }
  </style>

</head>
<body>
  <h1>Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2atrial of QBS72S in breast cancer brain metastases - PMC</h1>
  
  <div class="share-block">
    <span>üîó ÂàÜ‰∫´ÈÄôÁØáÊëòË¶ÅÔºö</span>
    <a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Farticles%2Fadaptive-cohort-design-and-lat1-expression-scale-study-protocol-for-a-phase-2atrial-of-qbs72s-in-breast-cancer-brain-metastases-pmc-summary.html" target="_blank" title="Facebook">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M512 256C512 114.6 397.4 0 256 0S0 114.6 0 256C0 376 82.7 476.8 194.2 504.5V334.2H141.4V256h52.8V222.3c0-87.1 39.4-127.5 125-127.5c16.2 0 44.2 3.2 55.7 6.4V172c-6-.6-16.5-1-29.6-1c-42 0-58.2 15.9-58.2 57.2V256h83.6l-14.4 78.2H287V510.1C413.8 494.8 512 386.9 512 256h0z"/></svg>
    </a>
    <a href="https://x.com/intent/tweet?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Farticles%2Fadaptive-cohort-design-and-lat1-expression-scale-study-protocol-for-a-phase-2atrial-of-qbs72s-in-breast-cancer-brain-metastases-pmc-summary.html&text=Adaptive%20cohort%20design%20and%20LAT1%20expression%20scale%3A%20study%20protocol%20for%20a%20Phase%202atrial%20of%20QBS72S%20in%20breast%20cancer%20brain%20metastases%20-%20PMC" target="_blank" title="X">
      <svg xmlns="http://www.w3.org/2000/svg" x="0px" y="0px" width="100" height="100" viewBox="0 0 50 50">
<path d="M 11 4 C 7.134 4 4 7.134 4 11 L 4 39 C 4 42.866 7.134 46 11 46 L 39 46 C 42.866 46 46 42.866 46 39 L 46 11 C 46 7.134 42.866 4 39 4 L 11 4 z M 13.085938 13 L 21.023438 13 L 26.660156 21.009766 L 33.5 13 L 36 13 L 27.789062 22.613281 L 37.914062 37 L 29.978516 37 L 23.4375 27.707031 L 15.5 37 L 13 37 L 22.308594 26.103516 L 13.085938 13 z M 16.914062 15 L 31.021484 35 L 34.085938 35 L 19.978516 15 L 16.914062 15 z"></path></svg>
    </a>
    <a href="https://www.threads.net/intent/post?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Farticles%2Fadaptive-cohort-design-and-lat1-expression-scale-study-protocol-for-a-phase-2atrial-of-qbs72s-in-breast-cancer-brain-metastases-pmc-summary.html&text=Adaptive%20cohort%20design%20and%20LAT1%20expression%20scale%3A%20study%20protocol%20for%20a%20Phase%202atrial%20of%20QBS72S%20in%20breast%20cancer%20brain%20metastases%20-%20PMC" target="_blank" title="Threads">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M64 32C28.7 32 0 60.7 0 96V416c0 35.3 28.7 64 64 64H384c35.3 0 64-28.7 64-64V96c0-35.3-28.7-64-64-64H64zM294.2 244.3c19.5 9.3 33.7 23.5 41.2 40.9c10.4 24.3 11.4 63.9-20.2 95.4c-24.2 24.1-53.5 35-95.1 35.3h-.2c-46.8-.3-82.8-16.1-106.9-46.8C91.5 341.8 80.4 303.7 80 256v-.1-.1c.4-47.7 11.5-85.7 33-113.1c24.2-30.7 60.2-46.5 106.9-46.8h.2c46.9 .3 83.3 16 108.2 46.6c12.3 15.1 21.3 33.3 27 54.4l-26.9 7.2c-4.7-17.2-11.9-31.9-21.4-43.6c-19.4-23.9-48.7-36.1-87-36.4c-38 .3-66.8 12.5-85.5 36.2c-17.5 22.3-26.6 54.4-26.9 95.5c.3 41.1 9.4 73.3 26.9 95.5c18.7 23.8 47.4 36 85.5 36.2c34.3-.3 56.9-8.4 75.8-27.3c21.5-21.5 21.1-47.9 14.2-64c-4-9.4-11.4-17.3-21.3-23.3c-2.4 18-7.9 32.2-16.5 43.2c-11.4 14.5-27.7 22.4-48.4 23.5c-15.7 .9-30.8-2.9-42.6-10.7c-13.9-9.2-22-23.2-22.9-39.5c-1.7-32.2 23.8-55.3 63.5-57.6c14.1-.8 27.3-.2 39.5 1.9c-1.6-9.9-4.9-17.7-9.8-23.4c-6.7-7.8-17.1-11.8-30.8-11.9h-.4c-11 0-26 3.1-35.6 17.6l-23-15.8c12.8-19.4 33.6-30.1 58.5-30.1h.6c41.8 .3 66.6 26.3 69.1 71.8c1.4 .6 2.8 1.2 4.2 1.9l.1 .5zm-71.8 67.5c17-.9 36.4-7.6 39.7-48.8c-8.8-1.9-18.6-2.9-29-2.9c-3.2 0-6.4 .1-9.6 .3c-28.6 1.6-38.1 15.5-37.4 27.9c.9 16.7 19 24.5 36.4 23.6l-.1-.1z"/></svg>
    </a>
  </div>

  <div style="text-align: center;"><img src="https://i.imgur.com/H4JFuyI.png" alt="News Cover Image" style="max-width: 100%; height: auto; border-radius: 12px; margin-bottom: 1.5em;"></div>
  <div class="lang-switcher">
    <button class="lang-btn active" data-lang="zh">‰∏≠Êñá</button><button class="lang-btn " data-lang="en">English</button><button class="lang-btn " data-lang="jp">Êó•Êú¨Ë™û</button>
  </div>
  
  <div class="ads-block" style="margin: 2.5em 0; position: relative; text-align: center;">
    <a href="https://cancerfree.io/" target="_blank" style="display: inline-block; position: relative;">
      <img src="https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcQI9CDgh7JwzUGH4QTfT5Su2MGI3gUURdf3Tw&s" alt="Advertisement" style="width: 100%; border-radius: 12px; box-shadow: 0 2px 6px rgba(0,0,0,0.1);">
      <div style="
        position: absolute;
        top: 8px;
        right: 8px;
        background: rgba(0, 0, 0, 0.6);
        color: white;
        font-size: 0.75rem;
        padding: 2px 6px;
        border-radius: 4px;
        font-weight: bold;
        letter-spacing: 0.5px;
      ">
        Âª£Âëä
      </div>
    </a>
  </div>
  
  <div class="lang-content" data-lang="zh" style="">This is a comprehensive list of references from a research article focusing on leptomeningeal brain metastases, particularly in lung cancer. Here's a breakdown of what the references cover, categorized for clarity:

**I. Leptomeningeal Disease & Liquid Biopsy (General)**

*   **Alix-Panabieres & Pantel (2016):**  A review of the clinical applications of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) as liquid biopsies. This sets the context for using CSF for genetic analysis.
*   **Mouliere et al. (2018):**  Demonstrates the ability to detect DNA fragmentation and copy number alterations in CSF from glioma patients using next-generation sequencing.  This is a foundational study for CSF analysis.
*   **Pentsova et al. (2016):**  Describes the use of next-generation sequencing of CSF to evaluate cancers of the central nervous system.
*   **Razavi et al. (2019):**  Identifies the sources of plasma ctDNA variants using high-intensity sequencing.  Important for understanding the origin of DNA found in CSF.
*   **White et al. (2021):**  A study specifically showing the detection of cell-free DNA fragmentation and copy number alterations in CSF from glioma patients.

**II. Lung Cancer & Brain Metastases (Specific to the Article's Focus)**

*   **Li et al. (2018):**  A key finding: recurrently mutated genes differ between leptomeningeal and solid lung cancer brain metastases.  This highlights a potential biological difference in how these metastases develop.
*   **Li et al. (2016):**  Shows that tumor DNA in CSF reflects the clinical course in a patient with melanoma leptomeningeal brain metastases.
*   **Pan et al. (2015):**  Demonstrates the detection of brain tumor mutations in CSF.
*   **Li et al. (2018):**  A study showing that recurrently mutated genes differ between leptomeningeal and solid lung cancer brain metastases.
*   **Gu et al. (2015):**  Demonstrates the detection of brain tumor mutations in CSF.

**III.  General Leptomeningeal Disease & CSF Analysis**

*   **Alix-Panabieres & Pantel (2016):** A review of the clinical applications of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) as liquid biopsies.
*   **Mouliere et al. (2018):** Demonstrates the ability to detect DNA fragmentation and copy number alterations in CSF from glioma patients using next-generation sequencing.
*   **Pentsova et al. (2016):** Describes the use of next-generation sequencing of CSF to evaluate cancers of the central nervous system.
*   **Razavi et al. (2019):** Identifies the sources of plasma ctDNA variants using high-intensity sequencing.
*   **White et al. (2021):** A study specifically showing the detection of cell-free DNA fragmentation and copy number alterations in CSF from glioma patients.

**IV. Clinical Trials (Potential Therapeutic Approaches)**

*   **ClinicalTrials.gov NCT02886585:** Phase II trial of pembrolizumab in CNS metastases.
*   **ClinicalTrials.gov NCT02123570:** Phase II trial of pembrolizumab in central nervous system metastases from multiple histologies.

**V.  Foundational Studies & Context**

*   **Gu et al. (2015):** Demonstrates the detection of brain tumor mutations in CSF.
*   **Li et al. (2016):** Shows that tumor DNA in CSF reflects the clinical course in a patient with melanoma leptomeningeal brain metastases.



**Key Takeaways from the References:**

*   **CSF as a Source of Information:** The references collectively emphasize the potential of CSF as a valuable source of genetic information for diagnosing and monitoring leptomeningeal brain metastases.
*   **Liquid Biopsy in CNS Cancer:**  They highlight the growing field of liquid biopsy, specifically focusing on CSF analysis.
*   **Biological Differences:** The study by Li et al. (2018) is particularly important, suggesting that leptomeningeal metastases may have distinct genetic characteristics compared to solid brain metastases.
*   **Therapeutic Potential:** The inclusion of clinical trial references indicates the hope for developing targeted therapies based on the genetic information obtained from CSF.</div><div class="lang-content" data-lang="en" style="display: none;">Okay, here's a breakdown of the provided text, focusing on extracting key information and organizing it.  I'm aiming to provide a structured summary of the research and its implications.

**Overall Topic:** Leptomeningeal Brain Metastases (specifically in the context of Lung Cancer) and the use of Cerebrospinal Fluid (CSF) analysis for diagnosis and monitoring.

**1. What are Leptomeningeal Brain Metastases?**

*   These are metastases (spread of cancer) that occur within the meninges ‚Äì the membranes surrounding the brain and spinal cord. They are a particularly challenging form of brain metastasis.

**2. Key Research Areas & Findings (Based on the provided citations):**

*   **CSF Analysis for Diagnosis & Monitoring:**
    *   **Cell-Free DNA (cfDNA):**  Research is focused on analyzing cfDNA found in CSF. This cfDNA can provide information about the tumor's genetic makeup and how it's evolving.
    *   **Mutation Detection:**  CSF cfDNA analysis can detect mutations in tumor DNA, providing insights into the cancer's characteristics.
    *   **Clinical Course Reflection:**  Changes in cfDNA levels and mutations in CSF can reflect the patient's overall clinical course.
    *   **Source Identification:** cfDNA analysis can help identify the origin of the tumor cells.
*   **Genetic Differences:**
    *   **Leptomeningeal vs. Solid Tumors:**  Studies have found that lung cancer that spreads to the meninges (leptomeningeal metastases) often has different genetic mutations compared to the primary lung tumor located elsewhere in the body.
*   **Liquid Biopsy Potential:**
    *   **Non-invasive Monitoring:** CSF analysis (a form of liquid biopsy) offers a less invasive way to monitor the cancer compared to traditional brain biopsies.
*   **Clinical Trials:**
    *   **Immunotherapy Trials:** Clinical trials are underway to evaluate the use of immunotherapies (Pembrolizumab, and others) for patients with leptomeningeal metastases.

**3. Specific Citations & Their Contributions (Summarized):**

*   **Mouliere et al. (2018):** Showed that CSF cfDNA analysis can detect copy number alterations in glioma patients.
*   **Razavi et al. (2019):**  Demonstrated how high-intensity sequencing can identify the sources of cfDNA variants in plasma.
*   **Pentsova et al. (2016):**  Used next-generation sequencing of CSF to evaluate cancers of the central nervous system.
*   **Li et al. (2016):** Found genetic differences between leptomeningeal and solid lung cancer brain metastases.
*   **White et al. (2021):** Showed that cfDNA from CSF can be used to detect leptomeningeal disease.
*   **Li et al. (2018):** Showed that CSF cfDNA can reflect the clinical course in melanoma patients with leptomeningeal metastases.
*   **AlixPanabieres & Pantel (2016):** Discussed the clinical applications of liquid biopsies (including CSF analysis).

**4. Clinical Trials Mentioned:**

*   Trials are evaluating the use of immunotherapies like Pembrolizumab for patients with leptomeningeal metastases.

**5. Data Availability:**

*   No datasets were generated or analyzed for this study.

**In essence, the research highlights the growing importance of CSF analysis, particularly cfDNA analysis, as a valuable tool for diagnosing, monitoring, and potentially treating patients with leptomeningeal brain metastases, especially in the context of lung cancer.**



Do you want me to elaborate on any specific aspect of this summary, or perhaps focus on a particular citation?</div><div class="lang-content" data-lang="jp" style="display: none;">Okay, here's a breakdown of the provided text, extracting key information and organizing it for clarity.  I'm focusing on the information relevant to leptomeningeal brain metastases and the use of liquid biopsies (CSF analysis).

**Summary: Leptomeningeal Brain Metastases & Liquid Biopsies (CSF Analysis)**

This text discusses the challenges of diagnosing and treating leptomeningeal brain metastases (LBM), a rare and aggressive form of cancer spread to the membranes surrounding the brain and spinal cord.  It highlights the emerging role of liquid biopsies, specifically analyzing cerebrospinal fluid (CSF), to improve diagnosis, understand the disease, and potentially guide treatment.

**Key Points & Findings:**

*   **Leptomeningeal Brain Metastases (LBM):**
    *   A rare and aggressive form of cancer spread.
    *   Difficult to diagnose and treat.
*   **Liquid Biopsies (CSF Analysis):**
    *   **Emerging Tool:** CSF analysis is increasingly being used as a "liquid biopsy" to gain insights into LBM.
    *   **Advantages:**  Offers a less invasive way to obtain tumor information compared to traditional brain biopsies.
    *   **What's Analyzed:** CSF is analyzed for:
        *   **Cell-Free DNA (cfDNA):** Fragments of DNA released by tumor cells.  Analysis of cfDNA can reveal:
            *   **Mutations:** Identifying specific genetic mutations in the tumor.
            *   **Copy Number Alterations:** Changes in the amount of DNA.
            *   **Fragmentation Patterns:**  Information about tumor activity.
        *   **Circulating Tumor Cells (CTCs):**  Rare tumor cells found in the CSF.
*   **Specific Findings & Research:**
    *   **Mutation Identification:** CSF cfDNA analysis can identify recurrently mutated genes in LBM.
    *   **Clinical Course Reflection:**  CSF cfDNA analysis can reflect the clinical course of the disease.
    *   **Source Identification:**  Analysis can help determine the origin of the tumor cells.
    *   **Differences from Solid Tumors:**  Research suggests that the genetic mutations found in LBM can differ from those found in the primary solid tumor.
*   **Clinical Trials:** Several clinical trials are underway exploring the use of immunotherapy drugs (Pembrolizumab, and other immune checkpoint inhibitors) in patients with CNS metastases.
*   **Data Availability:** No datasets were generated or analyzed for this specific article.

**References & Trials Mentioned (ClinicalTrials.gov IDs):**

*   **NCT02886585:** Phase II trial of pembrolizumab in central nervous system metastases from multiple histologies.
*   **NCT02123570:** Phase II trial of pembrolizumab in central nervous system metastases from multiple histologies.

**Overall Significance:**

The text emphasizes the potential of CSF liquid biopsies to improve the management of LBM by providing valuable information about the tumor's genetic makeup and behavior. This information can potentially lead to more targeted and effective treatments.

Let me know if you'd like me to elaborate on any specific aspect of this information!</div>
  <p style="text-align:center; margin-top: 2em;">
    <a href="./adaptive-cohort-design-and-lat1-expression-scale-study-protocol-for-a-phase-2atrial-of-qbs72s-in-breast-cancer-brain-metastases-pmc-seo.html">üëâ Êü•ÁúãÂéüÊñá / Full Article</a>
  </p>
  <script>
    document.querySelectorAll('.lang-btn').forEach(btn => {
      btn.addEventListener('click', () => {
        const lang = btn.dataset.lang;
        document.querySelectorAll('.lang-btn').forEach(b => b.classList.remove('active'));
        btn.classList.add('active');
        document.querySelectorAll('.lang-content').forEach(div => {
          div.style.display = div.dataset.lang === lang ? '' : 'none';
        });
      });
    });
  </script>
</body>
</html>